Purdue Pharma has announced the availability of Intermezzo sublingual tablet CIV in 1.75mg and 3.5mg dosage strengths for insomnia characterized by middle-of-the-night awakenings followed by difficulty returning to sleep.
Intermezzo (zolpidem tartrate), which contains a bicarbonate-carbonate buffer, is available in spearmint-flavored sublingual tablets that are placed under the tongue and allowed to disintegrate completely before swallowing. The product is available on prescription in retail pharmacies in the US, the company said.
Purdue Pharma president and CEO John Stewart said: “We are confident that healthcare professionals will find Intermezzo to be a valuable therapeutic option.”
